Developed by the Japanese firm Kowa Company, K-911—chemically known as bimatoprost grenod—functions as a prostanoid FP receptor agonist. The drug distinguishes itself by incorporating a nitric oxide-donating moiety, a technology originally discovered by the French pharmaceutical company Nicox S.A. Kowa secured exclusive global rights for the drug, excluding specific regions in Asia, through licensing agreements finalized between 2024 and 2025.
FDA Accepts Kowa’s New Glaucoma Drug Application for Review
The U.S. Food and Drug Administration has officially accepted the New Drug Application for K-911, a novel treatment designed to lower intraocular pressure in patients suffering from glaucoma and ocular hypertension. Kowa Research Institute submitted the filing in June, setting an April 30, 2027, target date for a final decision.
The therapeutic mechanism of K-911 addresses intraocular pressure through dual pathways. It stimulates conventional outflow via the trabecular meshwork and Schlemm’s canal through nitric oxide, while simultaneously enhancing unconventional uveoscleral outflow through bimatoprost. This dual-action approach represents a significant step in Kowa’s strategy to expand its ophthalmic portfolio and offer alternative treatment options for patients managing chronic ocular conditions.
Comments (0)
No comments yet. Be the first!